Last edition
News about "Wegovy"
Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.
Wegovy | 17/09/2025 | By Dineshwori
Novo Nordisk to Cut 9,000 Jobs in Global Restructuring Amid Market Pressures
Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss drug Wegovy and diabetes treatment Ozempic, has announced plans to cut 9,000 jobs worldwide—around 11 to 12 per cent of its workforce—as part of a major restructuring programme.
Wegovy | 10/09/2025 | By Darshana
Wegovy Outperforms Tirzepatide, Slashes Cardiovascular Risk by 57 Percent
Wegovy showed a significant 29 percent risk reduction for heart attack, stroke and death from any cause compared with Tirzepatide (over an average follow-up of 8.3 months for Wegovy and 8.6 months for Tirzepatide.
Wegovy | 01/09/2025 | By Dineshwori
Novo Nordisk's Wegovy Approved for Treatment of MASH in Adults with Liver Fibrosis
The US FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to Novo Nordisk.
Wegovy | 16/08/2025 | By Dineshwori | 121
Novo Nordisk Reports 18% H1 Sales Growth, Lowers H2 Outlook for Wegovy and Ozempic
Novo Nordisk has announced its financial results for the first half of 2025, ending June 30, with sales rising 18 percent at constant exchange rates (CER) to DKK 154.9 billion (USD 24.78 billion).
Wegovy | 06/08/2025 | By Dineshwori | 688
FDA-Approved Wegovy Now Easier to Access via Novo Nordisk's New Telehealth Initiative
In March 2025, Novo Nordisk launched NovoCare® Pharmacy to provide direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost.
Wegovy | 30/04/2025 | By Abha | 193
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy